DaShenLin Pharmaceutical Group (603233) Stock Overview
Manufactures, distributes, and retails pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
603233 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
DaShenLin Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.25 |
| 52 Week High | CN¥21.78 |
| 52 Week Low | CN¥15.50 |
| Beta | 0.64 |
| 1 Month Change | -9.54% |
| 3 Month Change | -6.91% |
| 1 Year Change | -0.40% |
| 3 Year Change | -43.05% |
| 5 Year Change | -57.89% |
| Change since IPO | 30.62% |
Recent News & Updates
Recent updates
We Think DaShenLin Pharmaceutical Group (SHSE:603233) Can Stay On Top Of Its Debt
Mar 14
Potential Upside For DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Not Without Risk
Feb 14Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)
Sep 30DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Sep 03DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital
Aug 20Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%
Jun 17Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?
Jun 09Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?
May 21Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings
May 06Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital
Apr 09Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E
Mar 17Shareholder Returns
| 603233 | CN Consumer Retailing | CN Market | |
|---|---|---|---|
| 7D | -3.3% | 0.9% | 4.9% |
| 1Y | -0.4% | -5.2% | 32.2% |
Return vs Industry: 603233 exceeded the CN Consumer Retailing industry which returned -5.2% over the past year.
Return vs Market: 603233 underperformed the CN Market which returned 32.2% over the past year.
Price Volatility
| 603233 volatility | |
|---|---|
| 603233 Average Weekly Movement | 4.7% |
| Consumer Retailing Industry Average Movement | 4.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 603233 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603233's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 43,532 | Guoqiang Ke | www.dslyy.com |
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
DaShenLin Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 603233 fundamental statistics | |
|---|---|
| Market cap | CN¥19.65b |
| Earnings (TTM) | CN¥1.14b |
| Revenue (TTM) | CN¥26.83b |
Is 603233 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603233 income statement (TTM) | |
|---|---|
| Revenue | CN¥26.83b |
| Cost of Revenue | CN¥17.61b |
| Gross Profit | CN¥9.22b |
| Other Expenses | CN¥8.08b |
| Earnings | CN¥1.14b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 24, 2026
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 34.36% |
| Net Profit Margin | 4.24% |
| Debt/Equity Ratio | 42.9% |
How did 603233 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 17:35 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DaShenLin Pharmaceutical Group Co., Ltd. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Qianyi Li | China International Capital Corporation Limited |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Mujun Shen | Citic Securities Co., Ltd. |